ClinicalTrials.gg

Program

DA-5222

A development code. Also written as “DA-5222-R1”, “DA-5222-R2” and “DA-5222-R3”.

Its studies are led by Dong-A ST.

Furthest: phase 1, since May 19, 20253 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dong-A ST32 open or runningphase 1since May 19, 2025May 19, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 19, 2025First studies: 2 phase 1 studies in HealthyFirst studyNCT06993181, NCT06993168
  2. Jun 23, 2025Phase 1 study in HealthyNCT07046715 · 40 enrolled · South Korea

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07046715Healthy · South Korea1CompletedAug 19, 202540
NCT06993181Healthy · Korea, Republic of1Not yet recruitingJul 202548
NCT06993168Healthy · Korea, Republic of1Not yet recruitingJul 202532

How it is read

Names in the registry

  • “DA-5222”, 3 entries
  • “DA-5222-R1”, 2 entries
  • “DA-5222-R2”, 2 entries
  • “DA-5222-R3”, 2 entries

Codes read as this program: DA5222.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.